Skip to main content
Equibles
ABT logo

ABT · Abbott Laboratories · Metrics

Track ABT — free

Use ABT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$108.52 +1.27 (+1.18%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$187.95B
Shares
1.73B
Volume · Nov 13 6.2M Avg daily vol (3M) 8.95M

ABT metrics

122 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$108.52
Market cap
$187.95B

Price action

23 metrics
Price change (1W)
-1.3%
Price change (30D)
+3.7%
Price change (3M)
-2.5%
Price change (6M)
+28.5%
Price change (YTD)
-13.4%
Price change (1Y)
-16.0%
Trailing year
Price change (5Y)
-15.5%
52-week high
$130.59
52-week low
$82.56
Change from 52-week high
-16.9%
Change from 52-week low
+31.4%
Annualized volatility
28.4%
Annualized volatility (3M)
25.8%
Implied volatility (30D)
26.1%
IV rank (1Y)
38.7
IV percentile (1Y)
43.3
Beta
0.1
RSI (14D)
54.1
Price vs SMA 50
+4.4%
Price vs SMA 200
+6.9%
Avg volume (3M)
8.95M
Relative volume
0.7
Average dollar volume
$944.85M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
1.73B

Valuation

12 metrics
P / E (TTM)
40.5
Trailing earnings · reciprocal yield 2.5%
PEG ratio
—
EV / revenue
4.5×
reciprocal yield 22.5%
EV / EBITDA
20.3×
reciprocal yield 4.9%
EV / EBIT
32.3×
reciprocal yield 3.1%
P / sales
3.9×
reciprocal yield 25.7%
P / book
3.7
reciprocal yield 27.1%
FCF yield
3.6%
TTM · current market cap
Buyback yield
0.8%
P / FCF
27.8
reciprocal yield 3.6%
P / operating cash flow
21.2
reciprocal yield 4.7%
Earnings yield
2.5%

Historical valuation

8 metrics
P / E historical average (3Y)
28.0×
reciprocal yield 3.6%
P / E historical average (5Y)
28.3×
reciprocal yield 3.5%
EV / revenue historical average (3Y)
4.9×
reciprocal yield 20.3%
EV / revenue historical average (5Y)
4.8×
reciprocal yield 21.0%
EV / EBIT historical average (3Y)
30.1×
reciprocal yield 3.3%
EV / EBIT historical average (5Y)
28.0×
reciprocal yield 3.6%
EV / EBITDA historical average (3Y)
20.5×
reciprocal yield 4.9%
EV / EBITDA historical average (5Y)
19.2×
reciprocal yield 5.2%

Dividends & buybacks

7 metrics
Dividend yield
2.3%
Trailing 12 months
Payout ratio
92.0%
Shareholder yield
3.1%
Dividend / share (TTM)
$2.52
Dividend growth YoY
+6.8%
Dividend growth streak
5+
Stored dividend history starts 2020
Last ex-dividend
2026-10-15

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-21

Profitability

9 metrics
Gross margin
56.9%
Operating margin
13.8%
Trailing 12 months
Net margin
9.7%
Gross profit (TTM)
$27.46B
Operating profit (TTM)
$6.65B
Net income (TTM)
$4.70B
Trailing 12 months
Diluted EPS (TTM)
$2.68
FCF margin
14.0%
Effective tax rate
28.4%

Per share

11 metrics
Revenue per diluted share (TTM)
$27.67
Gross profit per diluted share (TTM)
$15.76
Operating profit per diluted share (TTM)
$3.81
EBITDA per diluted share (TTM)
$6.06
Net income per diluted share (TTM)
$2.70
Operating cash flow per diluted share (TTM)
$5.08
Free cash flow per diluted share (TTM)
$3.88
Capital expenditures per diluted share (TTM)
$1.20
R&D per diluted share (TTM)
$1.90
Stock compensation per diluted share (TTM)
$0.42
Book value per share
$29.46

Growth

11 metrics
Revenue growth YoY
+14.5%
Year over year
Net income growth YoY
-44.0%
Revenue (TTM)
$48.23B
Trailing 12 months
EPS growth YoY
-43.6%
Shares change YoY
-0.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+0.5%
Revenue CAGR (5Y)
+5.1%
EPS CAGR (3Y)
-1.6%
EPS CAGR (5Y)
+8.3%
FCF CAGR (3Y)
-1.8%
FCF CAGR (5Y)
+5.3%

Quality

14 metrics
Return on equity
9.2%
Return on assets
4.3%
Debt / equity
0.6
Current ratio
1.5
EBITDA (TTM)
$10.56B
Free cash flow (TTM)
$6.76B
Quick ratio
1.0
Interest coverage
6.7
Net debt / EBITDA
2.5
Return on invested capital
6.1%
Trailing 12 months
Net cash
−$26.86B
Latest balance sheet
Cash & equivalents
$4.05B
Total assets
$108.25B
Total debt
$31.16B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$8.86B
Capital expenditures (TTM)
$2.10B
R&D (TTM)
$3.31B
SG&A (TTM)
$15.16B
Stock compensation (TTM)
$735.00M
R&D / revenue
6.9%
Stock compensation / revenue
1.5%

Ownership (13F)

9 metrics
13F filers
2,996
13F filer change QoQ
-133
Institutional ownership
81.0%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
11.4%
Private-fund adviser ownership
10.7%
Active holders' share change QoQ
-2.8%
Holder tenure
18.6
Price vs estimated holder cost
-13.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
19.6%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 1.9 days to cover
Days to cover
1.9d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$46.61M
Insider-sentiment score
16 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1800 CUSIP 002824100 13F (30d) 2389 filings 2259 filers Visit website Investor relations